• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: BMEDA-chelated Rhenium-186 nanoliposomes
Date Designated: 11/02/2023
Orphan Designation: Treatment of breast cancer with leptomeningeal metastases (LM)
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Plus Therapeutics, Inc.
4200 Marathon Blvd. # 200
Austin, Texas 78756
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-